Jimini Health today announced $17 million in seed funding from M13, Town Hall Ventures, LionBird, Zetta Venture Partners, and OneMind, bringing total funding to more than $25 million. The company is building clinician-supervised patient-facing AI infrastructure for large behavioral health provider organizations, enabling providers to deploy patient-facing AI safely, compliantly, and at scale, with licensed clinicians maintaining oversight of every patient interaction.
The Reality Health Systems Can No Longer Ignore
Patients at large behavioral health systems are already using AI for mental health support between appointments, without clinician visibility or control. This cultural shift is happening regardless of whether providers participate, placing new clinical, operational, and legal pressure on behavioral health organizations to respond.
More than 5.4 million U.S. adolescents and young adults now use AI chatbots for mental health advice. More than 1 million people a week have conversations with ChatGPT that include explicit indicators of suicidal planning or intent. Character.AI and Google have already settled wrongful death lawsuits brought by families of teenagers who died by suicide following unsupervised AI interactions.
“When 1 million people a week are discussing suicide with a product that was never designed to handle it, that’s not an edge case, it’s a systemic gap,” said Morgan Blumberg, Partner at M13. “Jimini is building the clinical infrastructure this category has never had: real supervision, real clinicians, real oversight.”
Meanwhile, in December 2025, the Centers for Medicare & Medicaid Services (CMS) and the FDA and CMS jointly announced some of the biggest steps forward to encourage safe clinical AI. With the coordinated ACCESS (CMS) and TEMPO (FDA) programs, CMS & FDA have sent a clear message that they welcome clinical, patient-facing tech-heavy care models. Numerous commercial payers pledged to follow suit in February. These changes and opportunities came faster than most expected, with numerous federal and state regulations as obstacles to enabling them, particularly around how to retain clinicians in the loop and in control.
How Jimini Enables Behavioral Health Systems to Safely Respond
Jimini’s platform, Sage, is the first and only patient-facing behavioral health AI designed from the ground up for deployment within large clinical organizations, not as a consumer app, but as a supervised member of the care team across the full spectrum of acuity, compliant with federal and state regulations and with clinicians in control.
For behavioral health system operators, Sage delivers three things:
Patient AI with clinicians in control, at scale: Care diagnostics and care decisions remain with the human clinical team. Every patient-Sage interaction is visible to the supervising clinician. Sage closely follows the plan of the human clinicians; it does not improvise.
Infrastructure built for regulated environments. Jimini’s safety frameworks were developed with clinical advisors from Harvard Medical School, Stanford, Yale, Dartmouth, and Google DeepMind. The company operates its own clinic, employing full-time licensed clinicians treating real patients on the platform. Every model update is evaluated against real-world outcomes before deployment and is ready to be deployed nationwide.
A reimbursement-ready model that moves the bottom line. As CMS and other layers expand pathways for AI-enabled care, Jimini is built to operate within those frameworks, not requiring workarounds.
“As CMS and other payers create new pathways for technology-enabled care, the stakes for getting AI right in behavioral health have never been higher,” said former Acting Administrator of the Centers for Medicare and Medicaid Services under President Obama and Jimini investor Andy Slavit. “Jimini is building what the industry needs.”
Why This Team Can Execute at Scale
Jimini was built by operators who have scaled tech and AI within regulated pharma and healthcare infrastructure before. CEO Luis Voloch co-founded Immunai, an AI-driven cancer immunotherapy company valued at over $1 billion. The founding team consists of President Mark Jacobstein, previous Chief Business Officer at Guardant Health, and Sahil Sud and Chiara Waingarten, first employees at Ribbon Health and Immunai, respectively. Chief Clinical Officer Dr. Bill Hudenko was a Professor at Dartmouth and a pioneer in digital methods for treating SMI, and Chief Commercial Officer Lynn Hamilton was CCO at Talkspace, where she secured payer contracts covering 40 million lives.
The clinical advisory board includes Dr. Sabine Wilhelm of Harvard Medical School, Dr. Seth Feuerstein of Yale Psychiatry, and Professor Nikos Daskalakis of Harvard and BU. Chief Scientist Dr. Johannes Eichstaedt’s peer-reviewed work in Nature Mental Health on AI safety in psychological settings underpins the platform’s clinical foundation. Moderna co-founder Robert Langer has joined the advisory board.
Partnering With Early Adopters, Large Behavioral Health Organizations
With this funding, Jimini will look to partner with several of the largest behavioral health provider organizations in the country and expand Sage’s clinical capabilities across comorbidities, care settings, and patient engagement modalities.
“It is entirely clear to us, and our early adopter clinical partners, that patient-facing LLMs will soon be a core part of patient care in behavioral health,” said Luis Voloch, CEO of Jimini. “We are looking for the forward-thinking health system partners who want to define what responsible AI looks like in this category – before it is defined for them.”
The company offers a structured implementation pathway designed for large, multi-site, hybrid in-person/virtual, with structured clinician training, EHR integration, and partner-specific customizations for clinical needs.
Health system operators interested in a partnership conversation can contact Jimini at partnerships@jiminihealth.com.